Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.48 |
| ▸ | MMP8 | P22894 | 6/20 | 0.47 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5251569 | 0.86 | PSEN1 (0.47) | NPSR1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5253603 | 0.85 | MMP8 (0.53) | NPSR1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5252095 | 0.84 | NPSR1 (0.50) | NPSR1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5249603 | 0.83 | MMP8 (0.51) | NPSR1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5915277 | 0.80 | NPSR1 (0.54) | NPSR1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL5303965 | 0.79 | MAPT (0.52) | NPSR1LMNAPSEN1PSEN2APH1B | |
| SCHEMBL15280429 | 0.78 | LMNA (0.58) | NPSR1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL5302286 | 0.77 | KDM4E (0.53) | NPSR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5250841 | 0.77 | ALDH1A1 (0.53) | LMNAPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28751377 | 0.75 | LMNA (0.52) | NPSR1LMNAALDH1A1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758884-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | ELAN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | claimed |
| WO-2005113542-A2 | N-CYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035884-A1 | N-cyclic sulfonamido inhibitors of gamma secretase | BACE1, BACE2, APH1B | NPSR1 39/4885LMNA 2570/4885PSEN1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.